ClearPoint Neuro Inc vs SPDR Gold Trust — how do they compare? ClearPoint Neuro Inc trades at $14.57 (market cap $454.21M), while SPDR Gold Trust trades at $406.57. The key difference: SPDR Gold Trust is trading nearer its 52-week high, ClearPoint Neuro Inc nearer its low. Which is the better fit depends on your goals.
| CLPT | GLD | |
|---|---|---|
Market Cap | $454.21M | — |
Sector | Health | — |
52-Week High | $29.60 | $495.90 |
52-Week Low | $8.66 | $305.27 |
Enterprise Value | $488.79M | — |
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $14.56, down slightly by 0.07% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue growth to $42 million but missed earnings estimates with a loss of $0.38 per share, reflecting ongoing investment in clinical and preclinical services. Despite negative net income margins and cash flow challenges, analyst consensus remains unanimously bullish with 3 buy ratings.
The outlook hinges on successful execution of growth initiatives in neuro drug delivery and regulatory progress with partners, though high valuation multiples and persistent losses pose significant risks. Near-term catalysts include Q3 2026 earnings and partner developments, but investors face volatility from operational cash burn and competitive pressures.
GLD, the SPDR Gold Shares ETF, trades at $405.25, up 0.65% today, reflecting strong momentum as gold benefits from cooling U.S. inflation data and safe-haven demand. The technical outlook is bullish with moving averages supporting upward trends, though oscillators signal overbought conditions. Recent news highlights gold's resilience amid geopolitical tensions and central bank buying, with spot gold surpassing $4,438 per ounce after July's CPI report showed a 2.5% annual core increase (Kitco, 2026-08-12).
The outlook for GLD remains positive driven by macroeconomic support, but risks include potential Fed policy shifts and profit-taking pressure. Investors may see opportunities in gold's role as a hedge, though high RSI levels suggest near-term volatility. Key resistance at $407 could test further gains, while support lies at $396.
Trailing returns across standard periods
Latest headlines on both assets
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →